Interactions between clarithromycin and digoxin in patients with end-stage renal disease

S. Hirata, S. Izumi, T. Furukubo, M. Ota, M. Fujita, T. Yamakawa, I. Hasegawa, Hisakazu Ohtani, Y. Sawada

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objective: To report a significant increase in the serum levels of digoxin associated with the use of clarithromycin in six patients undergoing renal replacement therapy. Case summary: All six patients were males with end-stage renal disease and in need of renal replacement therapy. Four patients were anuric. The mean age was 78.8 ± 5.8 (66-83) years. All patients except one, who was treated by hemofiltration, were treated by hemodialysis. All patients except one, who had been treated with metildigoxin (0.35 mg/week), were also taking digoxin (0.375 mg/week). Clarithromycin was administered at a dose of 200 - 400 mg/day for the treatment of bronchitis in all patients. The concomitant administration of clarithromycin increased serum digoxin levels from 1.8 - 4.0-fold in all cases. In two of six cases, a high probability of digoxin intoxication and suspicion of digoxin intoxication was evident. In three of six cases, serum digoxin levels increased within 12 days after the co-administration of clarithromycin, while in the other three cases, serum digoxin levels were increased 53 - 190 days after the administration of clarithromycin. Conclusion: The simultaneous administration of clarithromycin caused an increase in digoxin levels in six patients undergoing renal replacement therapy. The increase in the serum digoxin can be attributed to the inhibition of P-glycoprotein in the intestine and/or bile capillary rather than the kidney by clarithromycin since renal function was dramatically impaired, and four of the patients were anuric. The issue of why serum digoxin levels were increased so late in three patients undergoing renal replacement is unclear. However, this interaction seemed to be clinically significant even in ESRD patients, whose renal function was highly impaired. The simultaneous use of digoxin and clarithromycin sbould be avoided even in patients undergoing renal replacement therapy whose renal function is impaired, since digoxin levels may increase unexpectedly.

Original languageEnglish
Pages (from-to)30-36
Number of pages7
JournalInternational Journal of Clinical Pharmacology and Therapeutics
Volume43
Issue number1
Publication statusPublished - 2005 Jan
Externally publishedYes

Fingerprint

Clarithromycin
Digoxin
Chronic Kidney Failure
Renal Replacement Therapy
Kidney
Serum
Medigoxin
Hemofiltration
Bronchitis
P-Glycoprotein
Bile
Intestines
Renal Dialysis

Keywords

  • Clarithromycin
  • Digoxin
  • Eubacterium lentum
  • Hemodialysis
  • P-glycoprotein

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology (medical)

Cite this

Hirata, S., Izumi, S., Furukubo, T., Ota, M., Fujita, M., Yamakawa, T., ... Sawada, Y. (2005). Interactions between clarithromycin and digoxin in patients with end-stage renal disease. International Journal of Clinical Pharmacology and Therapeutics, 43(1), 30-36.

Interactions between clarithromycin and digoxin in patients with end-stage renal disease. / Hirata, S.; Izumi, S.; Furukubo, T.; Ota, M.; Fujita, M.; Yamakawa, T.; Hasegawa, I.; Ohtani, Hisakazu; Sawada, Y.

In: International Journal of Clinical Pharmacology and Therapeutics, Vol. 43, No. 1, 01.2005, p. 30-36.

Research output: Contribution to journalArticle

Hirata, S, Izumi, S, Furukubo, T, Ota, M, Fujita, M, Yamakawa, T, Hasegawa, I, Ohtani, H & Sawada, Y 2005, 'Interactions between clarithromycin and digoxin in patients with end-stage renal disease', International Journal of Clinical Pharmacology and Therapeutics, vol. 43, no. 1, pp. 30-36.
Hirata, S. ; Izumi, S. ; Furukubo, T. ; Ota, M. ; Fujita, M. ; Yamakawa, T. ; Hasegawa, I. ; Ohtani, Hisakazu ; Sawada, Y. / Interactions between clarithromycin and digoxin in patients with end-stage renal disease. In: International Journal of Clinical Pharmacology and Therapeutics. 2005 ; Vol. 43, No. 1. pp. 30-36.
@article{da3f647daef246b3b8510ed4f860ec6b,
title = "Interactions between clarithromycin and digoxin in patients with end-stage renal disease",
abstract = "Objective: To report a significant increase in the serum levels of digoxin associated with the use of clarithromycin in six patients undergoing renal replacement therapy. Case summary: All six patients were males with end-stage renal disease and in need of renal replacement therapy. Four patients were anuric. The mean age was 78.8 ± 5.8 (66-83) years. All patients except one, who was treated by hemofiltration, were treated by hemodialysis. All patients except one, who had been treated with metildigoxin (0.35 mg/week), were also taking digoxin (0.375 mg/week). Clarithromycin was administered at a dose of 200 - 400 mg/day for the treatment of bronchitis in all patients. The concomitant administration of clarithromycin increased serum digoxin levels from 1.8 - 4.0-fold in all cases. In two of six cases, a high probability of digoxin intoxication and suspicion of digoxin intoxication was evident. In three of six cases, serum digoxin levels increased within 12 days after the co-administration of clarithromycin, while in the other three cases, serum digoxin levels were increased 53 - 190 days after the administration of clarithromycin. Conclusion: The simultaneous administration of clarithromycin caused an increase in digoxin levels in six patients undergoing renal replacement therapy. The increase in the serum digoxin can be attributed to the inhibition of P-glycoprotein in the intestine and/or bile capillary rather than the kidney by clarithromycin since renal function was dramatically impaired, and four of the patients were anuric. The issue of why serum digoxin levels were increased so late in three patients undergoing renal replacement is unclear. However, this interaction seemed to be clinically significant even in ESRD patients, whose renal function was highly impaired. The simultaneous use of digoxin and clarithromycin sbould be avoided even in patients undergoing renal replacement therapy whose renal function is impaired, since digoxin levels may increase unexpectedly.",
keywords = "Clarithromycin, Digoxin, Eubacterium lentum, Hemodialysis, P-glycoprotein",
author = "S. Hirata and S. Izumi and T. Furukubo and M. Ota and M. Fujita and T. Yamakawa and I. Hasegawa and Hisakazu Ohtani and Y. Sawada",
year = "2005",
month = "1",
language = "English",
volume = "43",
pages = "30--36",
journal = "International Journal of Clinical Pharmacology and Therapeutics",
issn = "0946-1965",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "1",

}

TY - JOUR

T1 - Interactions between clarithromycin and digoxin in patients with end-stage renal disease

AU - Hirata, S.

AU - Izumi, S.

AU - Furukubo, T.

AU - Ota, M.

AU - Fujita, M.

AU - Yamakawa, T.

AU - Hasegawa, I.

AU - Ohtani, Hisakazu

AU - Sawada, Y.

PY - 2005/1

Y1 - 2005/1

N2 - Objective: To report a significant increase in the serum levels of digoxin associated with the use of clarithromycin in six patients undergoing renal replacement therapy. Case summary: All six patients were males with end-stage renal disease and in need of renal replacement therapy. Four patients were anuric. The mean age was 78.8 ± 5.8 (66-83) years. All patients except one, who was treated by hemofiltration, were treated by hemodialysis. All patients except one, who had been treated with metildigoxin (0.35 mg/week), were also taking digoxin (0.375 mg/week). Clarithromycin was administered at a dose of 200 - 400 mg/day for the treatment of bronchitis in all patients. The concomitant administration of clarithromycin increased serum digoxin levels from 1.8 - 4.0-fold in all cases. In two of six cases, a high probability of digoxin intoxication and suspicion of digoxin intoxication was evident. In three of six cases, serum digoxin levels increased within 12 days after the co-administration of clarithromycin, while in the other three cases, serum digoxin levels were increased 53 - 190 days after the administration of clarithromycin. Conclusion: The simultaneous administration of clarithromycin caused an increase in digoxin levels in six patients undergoing renal replacement therapy. The increase in the serum digoxin can be attributed to the inhibition of P-glycoprotein in the intestine and/or bile capillary rather than the kidney by clarithromycin since renal function was dramatically impaired, and four of the patients were anuric. The issue of why serum digoxin levels were increased so late in three patients undergoing renal replacement is unclear. However, this interaction seemed to be clinically significant even in ESRD patients, whose renal function was highly impaired. The simultaneous use of digoxin and clarithromycin sbould be avoided even in patients undergoing renal replacement therapy whose renal function is impaired, since digoxin levels may increase unexpectedly.

AB - Objective: To report a significant increase in the serum levels of digoxin associated with the use of clarithromycin in six patients undergoing renal replacement therapy. Case summary: All six patients were males with end-stage renal disease and in need of renal replacement therapy. Four patients were anuric. The mean age was 78.8 ± 5.8 (66-83) years. All patients except one, who was treated by hemofiltration, were treated by hemodialysis. All patients except one, who had been treated with metildigoxin (0.35 mg/week), were also taking digoxin (0.375 mg/week). Clarithromycin was administered at a dose of 200 - 400 mg/day for the treatment of bronchitis in all patients. The concomitant administration of clarithromycin increased serum digoxin levels from 1.8 - 4.0-fold in all cases. In two of six cases, a high probability of digoxin intoxication and suspicion of digoxin intoxication was evident. In three of six cases, serum digoxin levels increased within 12 days after the co-administration of clarithromycin, while in the other three cases, serum digoxin levels were increased 53 - 190 days after the administration of clarithromycin. Conclusion: The simultaneous administration of clarithromycin caused an increase in digoxin levels in six patients undergoing renal replacement therapy. The increase in the serum digoxin can be attributed to the inhibition of P-glycoprotein in the intestine and/or bile capillary rather than the kidney by clarithromycin since renal function was dramatically impaired, and four of the patients were anuric. The issue of why serum digoxin levels were increased so late in three patients undergoing renal replacement is unclear. However, this interaction seemed to be clinically significant even in ESRD patients, whose renal function was highly impaired. The simultaneous use of digoxin and clarithromycin sbould be avoided even in patients undergoing renal replacement therapy whose renal function is impaired, since digoxin levels may increase unexpectedly.

KW - Clarithromycin

KW - Digoxin

KW - Eubacterium lentum

KW - Hemodialysis

KW - P-glycoprotein

UR - http://www.scopus.com/inward/record.url?scp=12344296912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12344296912&partnerID=8YFLogxK

M3 - Article

C2 - 15704612

AN - SCOPUS:12344296912

VL - 43

SP - 30

EP - 36

JO - International Journal of Clinical Pharmacology and Therapeutics

JF - International Journal of Clinical Pharmacology and Therapeutics

SN - 0946-1965

IS - 1

ER -